Analysts See $-0.45 EPS for Foamix Pharmaceuticals Ltd. (FOMX); Zillow Group, Inc. (Z) Covered By 5 Bullish Analysts Last Week

April 21, 2018 - By Clifton Ray

Zillow Group, Inc. (NASDAQ:Z) Logo

Among 12 analysts covering Zillow Inc (NASDAQ:Z), 5 have Buy rating, 0 Sell and 7 Hold. Therefore 42% are positive. Zillow Inc had 32 analyst reports since July 31, 2015 according to SRatingsIntel. The rating was downgraded by Cowen & Co to “Underperform” on Friday, July 31. The stock has “Buy” rating by Benchmark on Wednesday, November 4. Benchmark maintained the stock with “Buy” rating in Wednesday, August 5 report. The firm has “Buy” rating given on Wednesday, January 10 by Morgan Stanley. The rating was maintained by Morgan Stanley with “Buy” on Wednesday, August 5. RBC Capital Markets maintained the stock with “Sector Perform” rating in Wednesday, August 5 report. The stock of Zillow Group, Inc. (NASDAQ:Z) earned “Equal-Weight” rating by Morgan Stanley on Friday, January 13. The stock has “Neutral” rating by Macquarie Research on Thursday, August 6. The stock has “Buy” rating by KeyBanc Capital Markets on Thursday, March 15. The company was downgraded on Wednesday, April 18 by Morgan Stanley. See Zillow Group, Inc. (NASDAQ:Z) latest ratings:

18/04/2018 Broker: Morgan Stanley Rating: Hold Downgrade
12/04/2018 Broker: KeyBanc Capital Markets Rating: Buy New Target: $63.0000 Maintain
13/04/2018 Broker: Deutsche Bank Rating: Hold
04/04/2018 Broker: DA Davidson Rating: Hold New Target: $60.0000 Initiate
15/03/2018 Broker: KeyBanc Capital Markets Rating: Buy New Target: $65.0 Maintain
13/03/2018 Broker: Inc. – Class C Capital Stock Rating: Morgan Stanley New Target: $50 55
09/02/2018 Broker: Cowen & Co Rating: Hold New Target: $47.0 Maintain
26/01/2018 Broker: KeyBanc Capital Markets Rating: Buy Upgrade
10/01/2018 Broker: Morgan Stanley Rating: Buy New Target: $50.0 Upgrade
10/01/2018 Broker: Cowen & Co Rating: Hold New Target: $45.0 Maintain

Analysts expect Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) to report $-0.45 EPS on May, 8.They anticipate $0.06 EPS change or 15.38% from last quarter’s $-0.39 EPS. After having $-0.46 EPS previously, Foamix Pharmaceuticals Ltd.’s analysts see -2.17% EPS growth. The stock increased 6.54% or $0.32 during the last trading session, reaching $5.21. About 75,751 shares traded. Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) has declined 13.02% since April 21, 2017 and is downtrending. It has underperformed by 24.57% the S&P500.

Among 3 analysts covering Foamix Pharmaceuticals (NASDAQ:FOMX), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Foamix Pharmaceuticals had 7 analyst reports since August 25, 2015 according to SRatingsIntel. The stock of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) earned “Hold” rating by Zacks on Tuesday, August 25. The company was initiated on Tuesday, December 5 by Guggenheim. The firm has “Buy” rating given on Friday, January 5 by H.C. Wainwright. The firm has “Buy” rating given on Tuesday, April 17 by H.C. Wainwright. H.C. Wainwright maintained it with “Buy” rating and $12.0 target in Wednesday, November 29 report.

Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular, rosacea, and other skin conditions in the United States, Germany, and France. The company has market cap of $195.64 million. The Company’s lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by methicillin-resistant staphylococcus aureus. It currently has negative earnings. The firm is also developing FMX103, a version of its minocycline foam FMX101, which is in Phase II clinical trial for the treatment of rosacea; and FDX104 that has completed Phase II clinical trial for the treatment of chemotherapy-induced rash.

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>